Shim

Critical Care Medicine · University of Virginia Physicians Group

Credentials: · ·

History

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection
National Heart, Lung, and Blood Institute · R01
PI · $2.2M · University of Virginia
2024–2029
Dissolved Phase Hyperpolarized Xenon-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology in Young Healthy e-Cigarette Users
National Institute on Drug Abuse · R01
Contact PI · $2.2M · Weill Medical Coll of Cornell Univ
2024–2029
Multi-Omic Characterization of COPD in Females
National Heart, Lung, and Blood Institute · R01
PI · $1.7M · Pennsylvania State Univ Hershey Med Ctr
2024–2028
Sexual Dimorphism in Susceptibility to Emphysematous Tissue Injury
National Heart, Lung, and Blood Institute · R01
Contact PI · $3M · Weill Medical Coll of Cornell Univ
2023–2027

The ROAM Research Study Therapy (LTOT) Version
Principal investigator · Recruiting
University of Virginia
2025–2030
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Principal investigator · Recruiting · Phase 2, Phase 3
Y. Michael Shim, MD
2024–2032
Hyperpolarized Xenon-129 MR Imaging of the Lung
Principal investigator · Recruiting · Phase 1, Phase 2
University of Virginia
2020–2025
Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant
Principal investigator · Active not recruiting · Phase 2
University of Virginia
2019–2038